top of page

Study: Survival Probability Better for the Unvaccinated

An American paper by B. Adhikari et al titled “Brief research report: impact of vaccination on antibody responses and mortality from severe COVID-19” published on 7 February 2024 finds that the COVID-19 survival probability of the unvaccinated (NVax) is better than the vaccinated (Vax).


The paper is 7 pages long. The study group is admittedly small with merely 152 adults who were patients at Ohio State University (OSU) hospitals. Most were over 50 years of age. The study period is between May 2020 and November 2022.


There were 40 non-COVID-19 patients, 15 Vax and 25 NVax.


There were 112 COVID-19 patients, 23 Vax and 89 NVax. Of these 112 patients, 66 were admitted after the vaccine rollout in December 2020 with 23 Vax (obviously) and 43 NVax.

Interestingly, mortality among Vax patients in this cohort was 70% compared with 37% in the NVax group, and overall survival rate was ~2 times higher in the NVax patients.
Further, in our cohort, COVID-19 patients who received complete vaccination series had increased mortality risk compared to those received incomplete series.

Again, the study group is admittedly small and relatively old. The researchers did consider the Charlson’s Comorbidity Index score (CCI) and made adjustments.


Figure 2: Kaplan-Meier survival analysis of SARS-CoV-2 infected patients before (A) and after (B) adjustment for Charlson’s Comorbidity Index (CCI).
Figure 2: Kaplan-Meier survival analysis of SARS-CoV-2 infected patients before (A) and after (B) adjustment for Charlson’s Comorbidity Index (CCI).

The researchers also analyzed plasma levels of IgG, IgA and IgM antibodies. I am not a doctor but at a glance, either there is not a huge difference between the Vax and NVax or it’s all over the place.


In some cases, there is a noticeable difference between survivors and non-survivors, probably indicating the impact of pre-existing health conditions. Other than that, IgA levels were higher in NVax than Vax. This is not a surprise as IgA is found in mucous membranes such as the respiratory and digestive tracts which the so-called vaccine does not induce.


Below is one observation made by the researchers:

Additionally, the SARS-CoV-2-N specific IgG/IgA/IgM Abs titers of the NVax patients were significantly higher than those of the Vax patients (Figure 3C). Interestingly, NVax patients with comorbidities had higher SARS-CoV-2 specific Ab levels compared to their Vax counterparts (Supplementary Figure 3), suggesting that the presence of comorbidities was not the sole contributing factor to the decreased Ab response. Thus, contrary to our expectations, we observed decreased Ab levels in the Vax compared to the NVax group.

Figure 3: SARS-CoV-2 S and N peptide-specific IgG, IgA and IgM Ab titers in different age groups and surviving and deceased COVID-19 infected patients.
Figure 3: SARS-CoV-2 S and N peptide-specific IgG, IgA and IgM Ab titers in different age groups and surviving and deceased COVID-19 infected patients.

In conclusion, the so-called vaccine doesn’t help or is even worse. As already stated, the study group is admittedly small, relatively old and limited to the state of Ohio. There is also the complex issue of comorbidities. One other weakness not mentioned in the paper is the lack of measurement of vitamin D levels. In any case, the researchers point out the obvious that

…the observation of higher mortality rates among 50+ Vax vs. NVAx patients with severe COVID-19 infection and respiratory failure is a matter of concern.
 

Be sure to subscribe to our mailing list so you get each new Opinyun that comes out!

 

Recent Posts

See All

Comments


Screen Shot 2021-12-09 at 4.49.31 PM.png

10% Off
Use Code: MERRYXMAS

MERCHANDISE!

bottom of page